Search

You searched for "registrars"

560 results found

Frequency-volume chart apps for nocturia: keeping urologists up at night

5 January 2022 | | URO - Functional / Reconstructive Urology, URO - Technology
Background Nocturia is a bothersome symptom and the leading cause of disturbed sleep in adults. It is extremely common, with 55% of men and 60% of women aged 50 waking at least once in the night, with a further 20%...

Fusion Bx 2.0 targeted prostate biopsy solution receives CE Mark

4 November 2019 | Research & Development
Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.

Together for 35 years: leading change in paediatric bowel and bladder health.

31 July 2026 | Awards, Conferences & Anniversaries
ERIC, The Children’s Bowel & Bladder Charity, returns with its biennial conference. This is a key event for healthcare professionals featuring cutting-edge research, interactive workshops, practical demonstrations and much more. Around 1 in 9 children and young people in the...

Join Prostate Cancer Research Free Webinar for Healthcare Professionals

11 December 2025
Managing Sexual Side Effects After Prostate Cancer: A Patient & Therapist Perspective Date: 20 January 2026 — 6.00pm (London)Register: https://zoom.us/webinar/register/WN_CstOkvaUSNSg_xlFI1Z27w Why attend?Sexual side effects remain one of the most challenging and under-discussed consequences of prostate cancer treatment. This focused webinar...
Prostate Cancer and Prostatic Diseases cover image.

Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel

1 September 2015 | | URO - Urologic Oncology
This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...

New drug hope for prostate cancer patients

16 January 2025
• Hormone therapy is used to slow the progression of advanced prostate cancer, but cancers often develop resistance and continue to grow.• Research reveals that patients with higher levels of heat shock proteins have worse outcomes.• Targeting these proteins with...

An update on antibiotic prophylaxis in TRUS-guided prostate biopsy

1 November 2016 | | URO - Urologic Oncology, URO - Infection
Since its inception in the 1980s, transrectal ultrasound (TRUS)-guided prostate biopsy has remained the standard tool for the histological diagnosis of prostate cancer. There are several advantages to this technique which have led to the widespread use of TRUS in...

How do we tackle social injustice in urological cancer?

2 December 2024 | | URO - Urologic Oncology
Socioeconomic status as an established determinant of health and associated injustices is well recognised. Confronting these injustices and creating a fairer healthcare system is an ongoing challenge for many governments. In Scotland, the devolved government has created the Scottish Index...

An update on lower pole stone management for 2015

1 March 2015 | | URO - Endourology & Stones
Introduction Urolithiasis is an increasing healthcare problem, with an estimated lifetime prevalence of up to 15% [1]. The number of interventions undertaken for stone disease has increased dramatically over recent years, particularly with respect to ureteroscopy and percutaneous nephrolithotomy (PCNL)...

COVID-19 cuts prostate cancer referrals in half

7 October 2020 | URO - Urologic Oncology
Charity warns that 3500 men risk being diagnosed with incurable cancer as referrals drop to lowest in 10 years Urgent referrals for urological cancers have dropped by half in England (49.5%) compared to the same period last year as the...

In conversation with Professor Christopher Chapple

1 March 2017 | URO - Core Urology
Professor Christopher Chappel. Prof Chapple, thank you for taking the time to chat with the Urology News team. Can we start by asking about your background and how you ended up in the field of urology? Early in my career...

Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer

1 January 2016 | | URO - Urologic Oncology, URO - Technology
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...